Search Follow us

Newron Pharmaceuticals (NWRN)

Business description

Newron is a CNS-focused biotech. Xadago (partnered with Zambon, US WorldMeds, Meiji Seika, Sequirus) for PD has been launched in Europe and the US. Other pipeline assets include Sarizotan (Phase III for RS) and Evenamide (Phase II for schizophrenia).

First Xadago sales; US decision by end Q116

QuickView | Pharmaceutical & healthcare | 09/11/2015

Xadago for the treatment of Parkinson’s disease is now generating initial sales in Europe following first launch in Germany, leading to royalty income to Newron from partner Zambon. The US regulatory review was recently extended by three months to end March 2016. Beyond Xadago, Newron has prioritised development of orphan drug sarizotan for Rett syndrome (a rare genetic condition) with a pivotal trial planned to start in Q415. Partnering candidate NW-3509 for schizophrenia is also advancing.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.CHF212.4m
Last closeCHF11.900
High / Low (52 weeks)CHF21.2 / CHF8.2
Stock market listingSW
Forecast net cash (€m)47.9
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual0.345.1(42.4)
Relative *4.145.5(39.5)

* % Relative to local index

Company news